Pegozafermin: "Pegozafermin demonstrated statistical significance on fibrosis improvement with weekly and every-two-week dosing"; Non-alcoholic steatohepatitis (89bio) - Oct 14, 2023 - Corporate Presentation: "≥1 Stage fibrosis improvement with no worsening of NASH (placebo-adjusted)"
P2 data • Non-alcoholic Steatohepatitis
|